COVID-19 VACCINE - NOVAVAX in a tie-up with India Serum Institute   


Aug 6 (Lagos) - USA based biotech Novavax Inc announced it has entered into a supply and license agreement with the Serum Institute of India for the development and commercialization of its Covid-19 vaccine candidate.


The Indian company will have exclusive rights for the vaccine in India during the term of the deal and non exclusive rights during the 'pandemic period' and all countries except those countries designated by the World Bank as Upper middle or high income countries. 


Novavax received more than $1.5 billion funding under President's Warp Speed programme to quickly develop a Covid-19 vaccine. The company expects to produce more 1-1.5 million vaccines by 2021. 


The stage-1 results proved to be positive and any analysts commented that they could be the best in class among all the vaccine candidates so far.


Serum Institute of India is World's Largest Vaccine Manufacturer by Number of Doses Produced and Sold Globally". Serum Institute is owned by the Poonawala family (CEO - Mr. A Poonawala (photo). 


"65%  of All Children in the World Receive at Least One Vaccine Manufactured by Serum Institute of India PVT. LTD."


"Serum Institute of India is ranked as India's No. 1 biotechnology company, manufacturing highly specialized life saving biologicals like vaccines using cutting edge genetic and cell based technologies, antisera and other medical specialties."





Shares of Novavax have jumped from under $5 a unit in February to $173 levels as of today in New York. 





Photo 1 - Serum Institute CEO Mr. Poonawala
Photo 2 - NOVAVAX headquarters in USA.
Photo 3 - India PM Modi at Serum Institute of India

reporting for easykobo.com on Thursday, August 6 2020 from Lagos, Nigeria
Copyright @ 2010-2019 Easykobo.com by Naija infotech & solar energy ltd. All rights reserved